ZYBERNO
Stock Report
Updated Aug 27, 2026

LIMINATUS PHARMA, INC. (LIMNW)

Healthcare • NASDAQ

$0.05

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
1.0/100
POOR BUSINESS
LIMINATUS PHARMA, INC. (LIMNW) scores 1/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-4,274.8%)
Debt-to-Equity (Solvency Risk):CRITICAL (12.20x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-839.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LIMINATUS PHARMA, INC. (LIMNW) stock report — Zyberno Score 1/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.05
Market Cap:$2.23M

Valuation Multiples (2)

P/B Ratio:7.42x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$656.57K

Price Action & Momentum (1)

% of 52-Week High:19.6%
B. Profitability Assessment

Return Metrics (5)

ROA:-544.2%
Reinvestment Rate:-0.4%
Fundamental Growth Rate (g):3.3%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$1.06K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.12x
Quick Ratio:1.12x
Cash Ratio:0.99x

Leverage Analysis (3)

Debt To Equity Ttm:12.20x
Debt-to-Equity Ratio:12.20x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-9.27x
Times Interest Earned:-9.27

Capital Structure (4)

Working Capital:352,044.00
Cash And Cash Equivalents:3,017,096.00
Long Term Debt:$0.00
Net Debt:-$1.57M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$4.33M

Bottom Line Performance (3)

-$12.85M
Income Before Tax:$0.00
Ebitda Ttm:-4,328,634.00

Operating Expenses (5)

Operating Expenses:4,299,187.00
R And D Expense:2,071,200.00
Sga Expense:3,299,187.00
Income Tax Expense:$0.00
Interest Expense:118,822.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$3.40M
Current Assets:$3.39M
Ppe Net:11,235.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,103,090.00
Current Liabilities:3,040,423.00
Long Term Debt:$0.00
Short Term Debt:$1.44M

Equity & Capital (3)

Equity:$300.61K
Retained Earnings:-$41.40M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:655,089.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$11.98M-$2.03M

Investment Activities (1)

Investing Cash Flow:-$575.00K

Financing Activities (3)

Financing Cash Flow:$3.59M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:518.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.49
-$0.49
Earnings Per Share Ttm:-$0.27

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.04

Book Value & Capital (2)

Book Value Per Share:$0.01
Cash Per Share:0.06

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.4%
Fundamental Growth Rate (g):3.3%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:LIMNW
Company Name:LIMINATUS PHARMA, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:48.40M
Shares Outstanding Basic:48.40M
Shares Outstanding Diluted:48.40M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-27 00:06:53 UTC
Data Timestamp:2026-08-27T00:06:53.030931
Scroll to Top